Research indicates that some weight regain is common when treatment stops
What you should do depends on how much time has passed since you were supposed to take it
A research study looking at how oral semaglutide works in people with type 2 diabetes in Canada, as part of local clinical practice (PIONEER REAL)

Additional caution may be appropriate in research involving: Additional Monitoring May Be Considered In Research Models Involving: Pregnancy and lactation-related research contexts, where limited safety data is available Severe gastrointestinal or delayed gastric-emptying research models, where GLP-1related pathways may influence gastrointestinal motility-related observations Pancreatic or pancreatitis-related research models, where metabolic and digestive-signaling pathways may require additional monitoring Gallbladder or biliary-related research models, where gastrointestinal and metabolic pathway modulation may influence biliary-related observations Diabetes or glucose-regulation research models involving concurrent glucose-lowering compounds, where glucose-homeostasis pathways may require closer monitoring Severe hepatic or renal impairment research models, where metabolic clearance and tolerability observations may differ Thyroid-related research models, including investigations involving endocrine-signaling pathways, thyroid-related biomarkers, or thyroid-cancer history models Additional Research Considerations Research conditions, protocol structure, research amount, and concurrent compounds may influence tolerability observations across experimental settings

We also frequently recommend semaglutide for other research-backed conditions, including the prevention and treatment of: Dementia or other cognitive disorders Heart disease Arthritis Depression Cancer Kidney disease Liver disease Inflammation Dont Forget About Tirzepatide Semaglutide isnt your only weight loss injection option at InterveneMD